SSAO Inhibitor Crystal Forms Stability and Preparation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective and stable forms of compounds for treating SSAO-related diseases, particularly non-alcoholic steatohepatitis, as existing inhibitors do not adequately target SSAO/VAP-1 enzymes and cells.
Innovation Solution
Development of crystal forms A and B of a compound of formula (IV) with specific X-ray powder diffraction patterns and thermal stability, which are used to prepare drugs that inhibit SSAO/VAP-1 enzyme and cell activity, involving preparation methods including slurry formation in organic solvents and controlled temperature conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing inhibitors are used to target SSAO/VAP-1 enzymes, then some inhibitory activity may be achieved, but the stability and effectiveness are insufficient
Solution Approach 1:
The patent changes the chemical structure parameters of the inhibitor compound (formula IV) by modifying the core scaffold, substituent groups, and molecular configuration to achieve optimal binding affinity and stability against SSAO/VAP-1 enzymes, resolving the contradiction between stability and effectiveness
Solution Approach 2:
The patent develops composite crystal forms of the inhibitor compound with specific crystalline structures (Crystal Form A, B, or C) that enhance both the stability and effectiveness of the inhibitor against SSAO/VAP-1 enzymes through improved molecular packing and reduced polymorphism
2Stability of the object's composition
If crystal forms are developed to improve stability, then storage and handling stability is enhanced, but the complexity of preparation and characterization increases
Solution Approach 1:
The patent performs preliminary optimization of crystallization conditions (solvent selection, temperature control, pH adjustment) to directly obtain the desired stable crystal forms during the preparation process, avoiding complex post-processing and characterization steps
Solution Approach 2:
The patent uses simple, readily available solvents and reagents in the preparation of crystal forms, and accepts that some trial crystal forms may need to be discarded in favor of the stable polymorphic forms, reducing the need for expensive and complex purification equipment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal forms of the compound demonstrate strong inhibitory activity against human recombinant VAP-1/SSAO enzyme and cells, showing good stability and potential for treating SSAO-related diseases like non-alcoholic steatohepatitis.
Implementation Method 1
SSAO/VAP-1 can be inhibited by semicarbazide, hence named as semicarbazide sensitive amine oxidase. The compound of formula (IV) and crystal form B of the compound of formula (IV) showed strong inhibitory activity against human recombinant VAP-1/SSAO enzyme
Implementation Method 2
the X-ray powder diffraction pattern of which has characteristic diffraction peaks at the following 2θ angles: 9.05±0.2°, 12.34±0.2°, 22.52±0.2°
Implementation Method 3
the X-ray powder diffraction pattern of which has characteristic diffraction peaks
Data Source
AI summary
Disclosed are a process route of a compound of a compound of formula (IV), a crystal form and a preparation method therefor. Also disclosed is an application of the crystal form in preparation of drugs for treating diseases associated with SSAO.